$CRDF

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement Under the terms of the Amendment, all disputed issues are resolved SAN DIEGO and NERVIANO, Italy, September 14, 2026 — Cardiff Oncology, Inc. (NASDAQ: CRDF) (“Cardiff”) and Ne

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m

Investing.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).

PACE GARY W purchased 687,285 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 ($1.00M total) on 2026-07-14.

Mohindru Mani (Chief Executive Officer) purchased 34,364 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 on 2026-07-14.

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 crdf-ex10_1.htm EX-10.1 EX-10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 14, 2026, between Cardiff Oncology, Inc., a Delaware corporation (the “ Company ”), and each purchaser identified on the signature p

Cardiff Oncology (Nasdaq: CRDF) announced a $10 million registered direct offering. It will sell 8,571,429 common shares with warrants at $1.05 per share, plus insider participation of 731,707 shares at $1.435 per share. Warrants exercise at $1.31, exercisable after six months and stockholder-authorized share increase. Closing expected July 16, 2026.

Mohindru Mani (Chief Executive Officer) purchased 24,703 shares of Cardiff Oncology, Inc. (CRDF) at $1.21 on 2026-06-18.

PACE GARY W purchased 30,000 shares of Cardiff Oncology, Inc. (CRDF) at $1.22 on 2026-06-18.